Compare PAYO & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAYO | PTGX |
|---|---|---|
| Founded | 2005 | 2006 |
| Country | United States | United States |
| Employees | N/A | 141 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 9.3B |
| IPO Year | 2021 | 2016 |
| Metric | PAYO | PTGX |
|---|---|---|
| Price | $7.14 | $138.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | $7.69 | ★ $108.23 |
| AVG Volume (30 Days) | ★ 2.3M | 498.6K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.05 | ★ 2.35 |
| Revenue | ★ $1,052,774,000.00 | N/A |
| Revenue This Year | $7.15 | $874.25 |
| Revenue Next Year | $10.28 | N/A |
| P/E Ratio | $142.60 | ★ $61.73 |
| Revenue Growth | ★ 7.68 | N/A |
| 52 Week Low | $4.08 | $62.24 |
| 52 Week High | $7.18 | $160.81 |
| Indicator | PAYO | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 54.05 | 49.01 |
| Support Level | $7.08 | $141.95 |
| Resistance Level | $7.16 | $151.24 |
| Average True Range (ATR) | 0.03 | 4.49 |
| MACD | -0.00 | -0.52 |
| Stochastic Oscillator | 44.44 | 42.25 |
Payoneer Global Inc is a financial technology company that enables small and medium-sized businesses (SMBs) to grow internationally through its diversified cross-border payments platform. It connects businesses, professionals, countries, and currencies, reducing the complexity of commerce and enabling customers to pay and get paid as easily as locally. The company offers a financial stack that includes cross-border AR/AP capabilities, funds management, working capital solutions, multicurrency accounts, and workforce management services. Its fully hosted platform provides multiple payment options with minimal integration, along with back-office functions and customer support. The company operates in Israel, the United States, and other countries.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.